Justin Kline
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Justin Kline has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Lishi Xie
University of Chicago 4 Committee on Immunology Chicago, Illinois
33 shared publications - Xiufen Chen
University of Chicago 4 Committee on Immunology Chicago, Illinois
29 shared publications - James Godfrey
Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
21 shared publications - Jonathan Trujillo
Department of Pathology, The University of Chicago, Chicago, Illinois
21 shared publications - Yuanyuan Zha
Department of Pathology, The University of Chicago, Chicago, Illinois
21 shared publications - Alan Cooper
Yale University School of Medicine, New Haven, CT
20 shared publications
Latest Publications
- 12 October 2026
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (6) , 852-855
CD19 CAR T-cell Escape in Large B-cell Lymphoma: Antigen Density Matters after All
Summary: In this issue of Blood Cancer Discovery, Corona, Gillmor, and colleagues show that quantitative CD19 density measured before chimeric antigen receptor (CAR) T-cell infusion stratifies progression-free survival in large B-cell lymphoma, yet low antigen density rarely reflects a genetic lesion at the CD19 locus itself, suggesting that other mechanisms of CD19 downregulation may promote CAR T-cell escape. Moreover, Newsam and colleagues offer one explanation—recurrent del(3p21.31)/RHOA loss that results in decreased CD19 in trans and impairs CAR T-cell efficacy. See related article by Corona et al., p. 940 See related article by Newsam et al., p. 957
- 12 October 2026
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (6) , 852-855
CD19 CAR T-cell Escape in Large B-cell Lymphoma: Antigen Density Matters after All
Summary: In this issue of Blood Cancer Discovery, Corona, Gillmor, and colleagues show that quantitative CD19 density measured before chimeric antigen receptor (CAR) T-cell infusion stratifies progression-free survival in large B-cell lymphoma, yet low antigen density rarely reflects a genetic lesion at the CD19 locus itself, suggesting that other mechanisms of CD19 downregulation may promote CAR T-cell escape. Moreover, Newsam and colleagues offer one explanation—recurrent del(3p21.31)/RHOA loss that results in decreased CD19 in trans and impairs CAR T-cell efficacy. See related article by Corona et al., p. 940 See related article by Newsam et al., p. 957
- 9 September 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
LymphGen-Sig: Integrating Genetic and Transcriptional States to Predict Therapeutic Response in Diffuse Large B-Cell Lymphoma
PURPOSE: Genetic classification may advance precision medicine in diffuse large B-cell lymphoma (DLBCL), but existing tools like LymphGen (LG) are limited by complexity and incomplete classification and do not incorporate nongenetic features that affect disease biology and therapeutic outcomes. To address these limitations, we developed LG-sig (LGsig), a gene expression–based platform that classifies all DLBCLs and harmonizes both genetic and nongenetic dimensions of the disease. METHODS: LGsig was built on the distinct subtype-specific gene expression signature of each LG class using paired genomic and transcriptomic data (National Cancer Institute/British Columbia Cancer Agency; N = 764). Model development was restricted to DLBCLs classified into MYD88 L265P and CD79B mutations (MCD), BCL6 translocation and NOTCH2 mutations (BN2), EZH2 mutations and BCL2 translocation (EZB), or SGK1 and TET2 mutations (ST2). Gene features were selected by differential gene expression, with 294 genes being optimal for classification using a nearest shrunken centroid classifier. LGsig classifications were designated as MCDsig , BN2sig , ST2sig , and EZBsig . The final model was applied to RNAseq from archival samples from the POLARIX trial (N = 678) to assess outcomes after polatuzumab vedotin-R-CHP (pola-R-CHP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for each LGsig subtype. RESULTS: LGsig accurately identified LG subtypes using transcriptional data alone and extended assignments to all previously LG-unclassified cases. Importantly, LG-unclassified DLBCLs reassigned by LGsig mirrored the transcriptional and clinical features of their corresponding LG counterparts, supporting their reclassification. In addition, LGsig reassigned LG A53 DLBCLs, characterized by aneuploidy and TP53 alterations, into more biologically and therapeutically relevant LGsig clusters. Finally, LGsig improved the performance of LG as a biomarker in the POLARIX study, by identifying distinct DLBCL subtypes exhibiting a survival benefit with pola-R-CHP over R-CHOP in both LG-classified and LG-unclassified cases. CONCLUSION: LGsig expands molecular classification beyond current genetic classifiers in DLBCL by integrating both genetic and transcriptional dimensions of the disease to better inform subtype-specific therapeutic strategies.
- 9 September 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
LymphGen-Sig: Integrating Genetic and Transcriptional States to Predict Therapeutic Response in Diffuse Large B-Cell Lymphoma
PURPOSE: Genetic classification may advance precision medicine in diffuse large B-cell lymphoma (DLBCL), but existing tools like LymphGen (LG) are limited by complexity and incomplete classification and do not incorporate nongenetic features that affect disease biology and therapeutic outcomes. To address these limitations, we developed LG-sig (LGsig), a gene expression–based platform that classifies all DLBCLs and harmonizes both genetic and nongenetic dimensions of the disease. METHODS: LGsig was built on the distinct subtype-specific gene expression signature of each LG class using paired genomic and transcriptomic data (National Cancer Institute/British Columbia Cancer Agency; N = 764). Model development was restricted to DLBCLs classified into MYD88 L265P and CD79B mutations (MCD), BCL6 translocation and NOTCH2 mutations (BN2), EZH2 mutations and BCL2 translocation (EZB), or SGK1 and TET2 mutations (ST2). Gene features were selected by differential gene expression, with 294 genes being optimal for classification using a nearest shrunken centroid classifier. LGsig classifications were designated as MCDsig , BN2sig , ST2sig , and EZBsig . The final model was applied to RNAseq from archival samples from the POLARIX trial (N = 678) to assess outcomes after polatuzumab vedotin-R-CHP (pola-R-CHP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for each LGsig subtype. RESULTS: LGsig accurately identified LG subtypes using transcriptional data alone and extended assignments to all previously LG-unclassified cases. Importantly, LG-unclassified DLBCLs reassigned by LGsig mirrored the transcriptional and clinical features of their corresponding LG counterparts, supporting their reclassification. In addition, LGsig reassigned LG A53 DLBCLs, characterized by aneuploidy and TP53 alterations, into more biologically and therapeutically relevant LGsig clusters. Finally, LGsig improved the performance of LG as a biomarker in the POLARIX study, by identifying distinct DLBCL subtypes exhibiting a survival benefit with pola-R-CHP over R-CHOP in both LG-classified and LG-unclassified cases. CONCLUSION: LGsig expands molecular classification beyond current genetic classifiers in DLBCL by integrating both genetic and transcriptional dimensions of the disease to better inform subtype-specific therapeutic strategies.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Transcriptomic analysis of T cells in discovery dataset.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Transcriptomic analysis of T cells in discovery dataset.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Survival of mice and tumor burden in OCI-Ly8 model following CAR T-cell engraftment.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Survival of mice and tumor burden in OCI-Ly8 model following CAR T-cell engraftment.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
CD19-directed chimeric antigen receptor (CAR) T-cell therapy has significantly advanced the treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). However, up to 60% of patients do not achieve a complete response. To uncover determinants of therapeutic efficacy, we analyzed the infusion products (IPs) of eight r/r DLBCL patients with distinct clinical responses to axicabtagene ciloleucel using single-cell transcriptomics. Compared with patients who exhibited progressive disease, IPs of complete responders demonstrated enriched signatures of type I interferon (IFN-I) signaling. Based on these findings, we developed a strategy to improve CD19-directed CAR T-cell treatment efficacy by incorporating IFN-I as an enhancer during the ex vivo manufacturing process, with IFN-I removal before CAR T-cell infusion to avoid in vivo toxicities. For both CD28- and 4-1BB–costimulated second-generation CARs, we found that low-strength IFN-I signaling enhanced CAR T-cell cytotoxicity and treatment efficacy against B-cell lymphoma and leukemia. Our low-strength IFN-I–enhanced CAR T-cell ex vivo manufacturing approach leverages an existing FDA-approved pharmacologic agent, circumvents in vivo interferon–associated toxicities, and remains fully compatible with current CAR constructs and manufacturing workflows. Together, our results establish IFN-I as a potent and costimulation-independent enhancer of CAR T-cell efficacy and provide a translationally feasible approach to enhance CAR T-cell therapies.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
CD19-directed chimeric antigen receptor (CAR) T-cell therapy has significantly advanced the treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). However, up to 60% of patients do not achieve a complete response. To uncover determinants of therapeutic efficacy, we analyzed the infusion products (IPs) of eight r/r DLBCL patients with distinct clinical responses to axicabtagene ciloleucel using single-cell transcriptomics. Compared with patients who exhibited progressive disease, IPs of complete responders demonstrated enriched signatures of type I interferon (IFN-I) signaling. Based on these findings, we developed a strategy to improve CD19-directed CAR T-cell treatment efficacy by incorporating IFN-I as an enhancer during the ex vivo manufacturing process, with IFN-I removal before CAR T-cell infusion to avoid in vivo toxicities. For both CD28- and 4-1BB–costimulated second-generation CARs, we found that low-strength IFN-I signaling enhanced CAR T-cell cytotoxicity and treatment efficacy against B-cell lymphoma and leukemia. Our low-strength IFN-I–enhanced CAR T-cell ex vivo manufacturing approach leverages an existing FDA-approved pharmacologic agent, circumvents in vivo interferon–associated toxicities, and remains fully compatible with current CAR constructs and manufacturing workflows. Together, our results establish IFN-I as a potent and costimulation-independent enhancer of CAR T-cell efficacy and provide a translationally feasible approach to enhance CAR T-cell therapies.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Transcriptomic analysis of T cell in validation dataset.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Transcriptomic analysis of T cell in validation dataset.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Expression of ISGs with IFN-α2 signaling.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Expression of ISGs with IFN-α2 signaling.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
CAR T-cell cytotoxicity on VAL cells and persistence after tumor stimulation.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
CAR T-cell cytotoxicity on VAL cells and persistence after tumor stimulation.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Type I interferon receptor expression and IFN-α2 titration in CAR T cells.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Type I interferon receptor expression and IFN-α2 titration in CAR T cells.